GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Metreleptin

Company
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
5 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

5 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Metreleptin and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02325674

    MEASuRE: Metreleptin Effectiveness And Safety Registry

    Chiesi Farmaceutici S.p.A. 100 participants Est. completion 2031-10-31 28 sites
    Other conditions: Generalised Lipodystrophy, Partial Lipodystrophy
    View official trial listing →
  • Recruiting NCT NCT05419037

    Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 90 participants Est. completion 2029-03-01 1 site
    Other conditions: Lipodystrophy
    View official trial listing →
  • Recruiting NCT NCT06305182

    Metreleptin in Anorexia Nervosa

    Not yet reported Gabriella Milos 50 participants Est. completion 2026-12-31 1 site Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Recruiting NCT NCT06484868

    Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

    Not yet reported Amryt Pharma 12 participants Est. completion 2028-02 12 sites Stand-alone
    Other conditions: Partial Lipodystrophy
    View official trial listing →
  • Recruiting NCT NCT06679270

    Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

    Not yet reported Chiesi Farmaceutici S.p.A. 24 participants Est. completion 2028-12 7 sites Stand-alone
    Other conditions: Familial Partial Lipodystrophy
    View official trial listing →
  • Completed NCT NCT00025883

    Leptin to Treat Lipodystrophy

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 103 participants Est. completion 2015-02 1 site Stand-alone
    Other conditions: Lipodystrophy
    View official trial listing →
  • Completed NCT NCT00050791

    Effects of Leptin Treatment on Weight Loss

    Not yet reported Rockefeller University 40 participants Est. completion 2009-06 1 site
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT00085982

    Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 11 participants Est. completion 2030-01-01 1 site Stand-alone
    Other conditions: Severe Insulin Resistance
    View official trial listing →
  • Completed NCT NCT00130117

    Study of Leptin for the Treatment of Hypothalamic Amenorrhea

    Not yet reported Beth Israel Deaconess Medical Center 20 participants Est. completion 2016-12 1 site
    Other conditions: Amenorrhea
    View official trial listing →
  • Completed NCT NCT00140205

    Pharmacokinetics of Leptin Administration During Fasting

    Not yet reported Beth Israel Deaconess Medical Center 15 participants Est. completion 2016-12 1 site Stand-alone
    Other conditions: Energy Deficiency Due to Short-term Fasting
    View official trial listing →
  • Completed NCT NCT00140231

    Role of Leptin in the Neuroendocrine and Immune Response to Fasting

    Not yet reported, Not yet reported Beth Israel Deaconess Medical Center 13 participants Est. completion 2016-12 1 site
    Other conditions: Fasting
    View official trial listing →
  • Completed NCT NCT00140244

    Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

    Not yet reported Beth Israel Deaconess Medical Center 7 participants Est. completion 2011-06 1 site
    Metabolic syndrome
    View official trial listing →
  • Terminated NCT NCT00265980

    Leptin in Human Energy and Neuroendocrine Homeostasis

    Not yet reported Columbia University 22 participants Est. completion 2013-07 1 site
    Other conditions: Obesity, Weight Loss
    View official trial listing →
  • Completed NCT NCT00392925

    A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

    Not yet reported AstraZeneca 177 participants Est. completion 2007-09 12 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT00461552

    Therapeutic Approaches to HAART-Induced Lipodystrophy

    Not yet reported University of Texas Southwestern Medical Center 23 participants Est. completion 2014-09 1 site
    Other conditions: HIV Infections, Lipodystrophy
    View official trial listing →
  • Completed NCT NCT00596934

    Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)

    Not yet reported Elif Oral 9 participants Est. completion 2009-03 1 site Stand-alone
    Other conditions: Fatty Liver Disease, Nonalcoholic
    View official trial listing →
  • Completed NCT NCT00657605

    Effects of Human Leptin Replacement

    Not yet reported University of Miami 3 participants Est. completion 2010-05-04 1 site
    Metabolic syndrome Other conditions: Obesity, Diabetes
    View official trial listing →
  • Completed NCT NCT00659828

    Effects of Leptin Replacement in Children

    Not yet reported University of Miami 1 participants Est. completion 2010-04-16 1 site
    Metabolic syndrome Other conditions: Obesity, Diabetes
    View official trial listing →
  • Completed NCT NCT00673387

    Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

    Not yet reported AstraZeneca 636 participants Est. completion 2009-10 36 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • No Longer Available NCT NCT00677313

    Expanded Access for Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

    Bristol-Myers Squibb
    View official trial listing →
  • Status unknown NCT NCT00691158

    A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

    Not yet reported Oregon Health and Science University 10 participants Est. completion 2024-07 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00710814

    Trial of Leptin Administration After Roux-en-Y Gastric Bypass

    Not yet reported, Not yet reported Columbia University 31 participants Est. completion 2014-07 1 site Stand-alone
    Other conditions: Overweight
    View official trial listing →
  • Completed NCT NCT00819234

    Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

    Not yet reported AstraZeneca 274 participants Est. completion 2009-11 33 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00896298

    Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

    Not yet reported, Not yet reported University of Texas Southwestern Medical Center 25 participants Est. completion 2014-11 1 site
    Other conditions: Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT01155180

    Leptin in the Maintenance of Reduced Body Weight

    Not yet reported Beth Israel Deaconess Medical Center 24 participants Est. completion 2016-12 1 site
    Other conditions: Obesity
    View official trial listing →
  • Terminated NCT NCT01235741

    A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

    Not yet reported AstraZeneca 213 participants Est. completion 2011-09 18 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Terminated NCT NCT01268644

    Effects of Metreleptin in Type 1 Diabetes Mellitus

    Not yet reported University of Texas Southwestern Medical Center 8 participants Est. completion 2014-08 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT01511016

    Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome

    Not yet reported Baylor College of Medicine 17 participants Est. completion 2011-10 1 site Stand-alone
    Other conditions: HIV Lipodystrophy
    View official trial listing →
  • Completed NCT NCT01679197

    Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

    Not yet reported University of Michigan 23 participants Est. completion 2016-07-13 1 site Stand-alone
    MASH Other conditions: Fatty Liver Disease, Nonalcoholic, Lipodystrophy
    View official trial listing →
  • Completed NCT NCT01778556

    Short-term Effects of Leptin in People With Lipodystrophy

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 25 participants Est. completion 2018-02-23 1 site Stand-alone
    Other conditions: Lipodystrophy
    View official trial listing →
  • Active, not recruiting NCT NCT02262806

    Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 29 participants Est. completion 2027-07-31 1 site
    Other conditions: Diabetes, Lipodystrophy, Hyperlipidemia
    View official trial listing →
  • Active, not recruiting NCT NCT02262832

    Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 24 participants Est. completion 2027-07-31 1 site
    Other conditions: Lipodystrophy, Diabetes, Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT02654977

    CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy

    Not yet reported University of Michigan 11 participants Est. completion 2019-11-14 1 site Stand-alone
    MASHMASLD Other conditions: Familial Partial Lipodystrophy
    View official trial listing →
  • Completed NCT NCT04026178

    Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

    Not yet reported Aegerion Pharmaceuticals, Inc. 11 participants Est. completion 2024-10-31 8 sites Stand-alone
    Other conditions: Generalized Lipodystrophy
    View official trial listing →
  • Completed NCT NCT04063488

    The Effects of Metreleptin in Congenital Leptin Deficiency

    Northwestern University 2 participants Est. completion 2021-08-13 1 site
    Other conditions: Congenital Leptin Deficiency (Disorder)
    View official trial listing →
  • Active, not recruiting NCT NCT05164341

    Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

    Not yet reported Chiesi Farmaceutici S.p.A. 69 participants Est. completion 2026-10-31 31 sites
    Other conditions: Partial Lipodystrophy
    View official trial listing →
  • Active, not recruiting NCT NCT05351164

    Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

    Not yet reported University of Michigan 4 participants Est. completion 2028-10 1 site Stand-alone
    Other conditions: Lipomatosis, Multiple Symmetrical
    View official trial listing →
  • Terminated NCT NCT06502990

    Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

    Not yet reported Amryt Pharma 1 participants Est. completion 2026-02-11 12 sites Stand-alone
    Other conditions: Generalized Lipodystrophy
    View official trial listing →
  • Completed NCT NCT06548100

    A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

    Not yet reported Regeneron Pharmaceuticals 9 participants Est. completion 2026-07-09 2 sites Stand-alone
    Other conditions: Generalized Lipodystrophy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Metreleptin, Myalept

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.